Real-world data of first-line treatment with pembrolizumab for non-small cell lung cancer with high PD-L1 expression (HOT/NJLCG2001)

被引：0

作者：

Yokouchi, H. ^{[1
]}

Mizugaki, H. ^{[2
]}

Ikezawa, Y. ^{[3
]}

Morita, R. ^{[4
]}

Tateishi, K. ^{[5
]}

Yokoo, K. ^{[6
]}

Sumi, T. ^{[7
]}

Kikuchi, H. ^{[8
]}

Nakamura, A. ^{[9
]}

Kobayashi, M. ^{[10
]}

Aso, M. ^{[11
]}

Tsukita, Y. ^{[12
]}

Yoshiike, F. ^{[13
]}

Furuta, M. ^{[14
]}

Tanaka, H. ^{[15
]}

Sekikawa, M. ^{[16
]}

Hachiya, T. ^{[17
]}

Nakamura, K. ^{[18
]}

Kitamura, Y. ^{[19
]}

机构：

[1] Hokkaido Canc Ctr, Dept Resp Med, Fukushima, Japan

[2] Japanese Fdn Canc Res, Canc Immunotherapy Dev, Adv Med Dev Ctr, Canc Inst Hosp, Koto Ku, Tokyo, Japan

[3] Oji Gen Hosp, Dept Resp Med, Tomakomai, Japan

[4] Akita Kousei Med Ctr, Thorac Oncol, Akita, Nishibukuro, Japan

[5] Shinshu Univ, Sch Med, 3-1-1 Asahi, Matsumoto, Nagano, Japan

[6] Teine Keijinkai Hosp, Dept Resp Med, Sapporo, Hokkaido, Japan

[7] Hakodate Goryoukaku Hosp, Dept Resp Med, Hakodate, Hokkaido, Japan

[8] JA Hokkaido Kouseiren Obihiro Kosei Gen Hosp, Dept Resp Med, Obihiro, Hokkaido, Japan

[9] Sendai Kousei Hosp, Dept Resp Med, Sendai, Miyagi, Japan

[10] Miyagi Canc Ctr, Resp Med, Natori, Miyagi, Japan

[11] Yamagata Prefectural Cent Hosp, Pulm Med, Yamagata, Japan

[12] Tohoku Univ, Dept Resp Med, Sendai, Miyagi, Japan

[13] Nagano Municipal Hosp, Dept Resp Med, Nagano, Japan

[14] Hokkaido Univ Hosp, Dept Resp Med, Sapporo, Hokkaido, Japan

[15] Hirosaki Univ, Dept Resp Med, Hirosaki, Aomori, Japan

[16] Steel Mem Muroran Hosp, Dept Resp Med, Muroran, Hokkaido, Japan

[17] Suwa Red Cross Hosp, Dept Resp Med, Suwa, Japan

[18] Natl Hosp Org Asahikawa Med Ctr, Dept Resp Med, Asahikawa, Hokkaido, Japan

[19] Kushiro City Gen Hosp, Dept Resp Med, Kushiro, Japan

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.10.373

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

335P

引用

页码：S1574 / S1574

页数：1

共 50 条

[41] Cost-Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels
Weng, Xiuhua
Luo, Shaohong
Lin, Shen
Zhong, Lixian
Li, Meiyue
Xin, Rao
Huang, Pinfang
Xu, Xiongwei
ONCOLOGY RESEARCH, 2020, 28 (02) : 117 - 125
[42] Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate
Alessandro Rizzo
British Journal of Cancer, 2022, 127 : 1381 - 1382
[43] Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate
Rizzo, Alessandro
BRITISH JOURNAL OF CANCER, 2022, 127 (08) : 1381 - 1382
[44] Real-world data analysis of PD-L1 expression and overall survival (OS) in advanced non-small cell lung cancer (aNSCLC)
Staib, J.
Sudarsanam, S.
Byfield, S. Dacosta
Kennedy, C.
Weiss, L.
ANNALS OF ONCOLOGY, 2019, 30 : 27 - 27
[45] Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer
Peng, Jianfeng
Zhang, Lemeng
Wang, Liping
Feng, Hui
Yao, Dongmei
Meng, Rui
Liu, Xiaomei
Li, Xiaohua
Liu, Ningbo
Tan, Bingxu
Huang, Zhaoqin
Li, Shanshan
Meng, Xiangjiao
RADIATION ONCOLOGY, 2023, 18 (01)
[46] Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer
Jianfeng Peng
Lemeng Zhang
Liping Wang
Hui Feng
Dongmei Yao
Rui Meng
Xiaomei Liu
Xiaohua Li
Ningbo Liu
Bingxu Tan
Zhaoqin Huang
Shanshan Li
Xiangjiao Meng
Radiation Oncology, 18
[47] Cost-effectiveness analysis of PD-L1 testing associated with pembrolizumab for first-line treatment of advanced non-small cell lung cancer in China
Wu, Yao
Tao, Libo
Liu, Chang
Wang, Fangxu
Sun, Shuang
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2025,
[48] Impact of Frailty on Outcomes of First-Line Pembrolizumab Monotherapy in a Real-World Population with Advanced Non-Small Cell Lung Cancer
Galan, Rocio Jimenez
Prado-Mel, Elena
de Sotomayor, Maria Alvarez
Martin, Laila Abdel-Kader
BIOLOGY-BASEL, 2023, 12 (02):
[49] Real-World longitudinal practice patterns in the use of PD-1 and PD-L1 inhibitors as First-Line therapy in patients with Non-Small cell lung cancer in the United States
Veluswamy, Rajwanth
Hirsch, Fred R.
Taioli, Emanuela
Wisnivesky, Juan
Strauss, Ross
Harrough, Douglas
Tang, Boxiong
Barnes, Gisoo
CANCER MEDICINE, 2022, 11 (22): : 4265 - 4272
[50] Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study
Kawachi, Hayato
Tamiya, Motohiro
Tamiya, Akihiro
Ishii, Seigo
Hirano, Katsuya
Matsumoto, Hirotaka
Fukuda, Yasushi
Yokoyama, Toshihide
Kominami, Ryota
Fujimoto, Daichi
Hosoya, Kazutaka
Suzuki, Hidekazu
Hirashima, Tomonori
Kanazu, Masaki
Sawa, Nobuhiko
Uchida, Junji
Morita, Mitsunori
Makio, Takeshi
Hara, Satoshi
Kumagai, Toru
INVESTIGATIONAL NEW DRUGS, 2020, 38 (01) : 211 - 218

← 1 2 3 4 5 →